September 4, 2008
Senetek Launches Pyratine-6(TM)
NAPA, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Senetek PLC (BULLETIN BOARD: SNKTY) , a life sciences company engaged in the development of technologies that target the science of healthy aging, announced today the launch of Pyratine-6(TM), representing the next generation of superior skincare products for the correction of visible signs of aging. In the 1990's Senetek developed kinetin, the cytokinin-based active ingredient in the successful Kinerase skincare line, and are now taking cytokinin technology further with Pyratine-6(TM).
Pyratine-6(TM)'s new cytokinin technology works faster than kinetin or any other product on the market in dramatically reducing roughness and redness starting in as little as two weeks, with full results on fine wrinkles, dryness, discoloration, and other signs of photodamage in twelve weeks of consistent use. Clinical studies showed improvement in pre-existing redness associated with rosacea, eczema, contact dermatitis and menopause.
Cytokinins are natural plant-derived growth factors that stimulate growth and differentiation. While they do not stimulate proliferation of human cells, cytokinins have proved to be superior anti-aging agents in skin cells. By functioning as antioxidants, they purge cellular debris and delay the aging process. The enhanced Pyratine-6(TM) cytokinin is the most effective and fastest acting cytokinin available today.
In a clinical study of 34 patients, Pyratine-6(TM) was well tolerated by 33 of the patients. Because it is non-acidic and without irritants, Pyratine-6(TM) shows 0 on a 4-point scale of irritation and can be used in conjunction with treatment procedures such as chemical peels, laser resurfacing, microdermabrasion and injectables. It has no know interactions with drugs or other products and, it can be used before the application of cosmetics and in conjunction with sunscreen and other enhancement products.
In an independent study by Dr. Jerry L. McCullough from the University of California, Irvine, et al published in the February 2008 Journal of Drugs in Dermatology, Dr. McCullough stated, "Treatment with Pyratine-6(TM) (0.1%) over 12 weeks improves roughness and skin moisturization in 2 weeks and hyperpigmentation and fine wrinkles in 4 weeks." Further, the report stated that adverse effects of Pyratine-6(TM) are "minimal" and "transient."
Pyratine-6(TM) will be available starting in September 2008 only through dermatologists, plastic surgeons and top medical spas across the country, providing its high efficacy and specialized benefits in a professional environment. For a list of physicians and medical spas carrying Pyratine-6(TM) call 888-GO-PYRATINE or 877-586-3747.
About Senetek, PLC
Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com/.
CONTACT: company, William O'Kelly of Senetek, PLC, +1-707-226-3900,ext. 102; or media, Michael Rogers, +1-212-255-7210,[email protected], for Senetek PLC
Web site: http://www.senetekplc.com/